Novartis AG ADR
USUSDNovartis AG ADR (MI:1NOVN) — Drug Manufacturers - General. Antal børser, hvor selskabets aktier handles: 7. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.
Om virksomheden
- Websted
- novartis.com
- Sektor
- Healthcare · Drug Manufacturers - General
- Hovedkontor
- BASEL, Switzerland
- Administrerende direktør
- Dr. Vasant Narasimhan M.D.
- Ansatte
- 75 267
- Grundlagt
- 1996
- Udestående aktier
- 1.91 mia. pr. 2025-12-31
- Free float
- 1.86 mia.
- Markedsværdi
- 276.48 mia. USD
- Insidere
- 0.01%
- Institutionelle investorer
- 7.27%
- Branche (SIC)
- Pharmaceutical Preparations
- Juridisk form
- MVII
- ISIN
- CH0012005267
- LEI
- 5493007HIVTX6SY6XD66
- Udbetalingsgrad
- 71.1%
- FCF
- 15.0 mia. USD61%
- Gæld
- 49.0 mia. USD2.6 år FCF
- Udbyttestreak
- 20 år
Beskrivelse
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Børser og tickere
| Børs | Ticker | Valuta | Pris | Type |
|---|---|---|---|---|
| US USA Stocks | NVSEF OTC | USD | 134.22 -0.23% | almindelige aktier |
| LSE London Stock Exchange | 0QLR IOB | CHF | 82.63 +0.00% | almindelige aktier |
| MI Borsa Italiana (Milan) | 1NOVN sekundær | EUR | 128.44 +2.42% | almindelige aktier |
| SW SIX Swiss Exchange | NOVN primær | CHF | 119.8 -0.13% | almindelige aktier |
| SW SIX Swiss Exchange | NOVNEE sekundær | CHF | 120.02 -1.80% | almindelige aktier |
| VI Vienna Stock Exchange | NOVN sekundær | EUR | 126.72 | almindelige aktier |
| XETRA Xetra | NOT sekundær | EUR | 126.82 +0.48% | almindelige aktier |
Udbytte
Novartis AG ADR (1NOVN) udbetaler udbytte uregelmæssigt. I løbet af de sidste 12 måneder blev der betalt 3.9091 EUR pr. Aktie (betalinger: 1). Det svarer til cirka 3.04% af den nuværende aktiekurs. Uafbrudt udbyttehistorik: 20 år.
| Ex-dato | Udbetaling | Beløb | % | Type | Ticker |
|---|---|---|---|---|---|
| 2026-03-10 | — | 3.9091 EUR | 3.0/3.0 % | — | MI:1NOVN |
Nyheder denne uge
Endnu ingen nyheder fra virksomhedens websted.
Største ejere
| Ejer | Andel | Aktier | Rapportdato |
|---|---|---|---|
| VANGUARD STAR FUNDS-Vang… | 1.35% | 27.43 mio. | 2026-07-31 |
| VANGUARD TAX-MANAGED FUN… | 0.9% | 18.24 mio. | 2026-06-30 |
| Fisher Asset Management,… | 0.76% | 15.52 mio. | 2026-06-30 |
| iShares Trust-iShares Co… | 0.67% | 13.69 mio. | 2026-08-31 |
| Goldman Sachs TRT II-Gol… | 0.6% | 12.19 mio. | 2026-07-31 |
| Artisan Partners Funds I… | 0.51% | 10.29 mio. | 2026-06-30 |
| Dodge & Cox Funds-Dodge… | 0.44% | 8.9 mio. | 2026-06-30 |
| Morgan Stanley | 0.43% | 8.73 mio. | 2026-06-30 |
| Dimensional Fund Advisor… | 0.4% | 8.12 mio. | 2026-06-30 |
| Fidelity Concord Street… | 0.35% | 7.12 mio. | 2026-07-31 |
| Primecap Management Comp… | 0.32% | 6.59 mio. | 2026-06-30 |
| iShares Trust-iShares MS… | 0.32% | 6.53 mio. | 2026-08-31 |
| LOOMIS SAYLES & CO L P | 0.26% | 5.24 mio. | 2026-06-30 |
| MFS Series Trust XVII-MF… | 0.26% | 5.22 mio. | 2026-06-30 |
| Bank of America Corporat… | 0.24% | 4.91 mio. | 2026-06-30 |
| VANGUARD SPECIALIZED FUN… | 0.23% | 4.66 mio. | 2026-07-31 |
| VANGUARD CHESTER FUNDS-V… | 0.21% | 4.25 mio. | 2026-06-30 |
| Franklin Resources, Inc. | 0.16% | 3.25 mio. | 2026-06-30 |
| Blackrock Inc. | 0.15% | 3.05 mio. | 2026-06-30 |
| Goldman Sachs Group Inc | 0.15% | 2.98 mio. | 2026-06-30 |
| Northern Trust Corporati… | 0.14% | 2.79 mio. | 2026-06-30 |
| DFA INVESTMENT DIMENSION… | 0.11% | 2.14 mio. | 2026-04-30 |
| LOOMIS SAYLES FUNDS II-L… | 0.07% | 1.42 mio. | 2026-06-30 |
| VANGUARD HORIZON FUNDS-V… | 0.06% | 1.21 mio. | 2026-06-30 |
| Franklin Mutual Series F… | 0.06% | 1.19 mio. | 2026-06-30 |
| JANUS INVESTMENT FUND-Ja… | 0.05% | 949 726 | 2026-06-30 |
| Principal Funds, Inc-Equ… | 0.05% | 945 091 | 2026-04-30 |
| Dimensional ETF Trust-Di… | 0.04% | 888 855 | 2026-04-30 |
| Franklin Mutual Series F… | 0.04% | 812 618 | 2026-06-30 |
| Dimensional ETF Trust-Di… | 0.04% | 716 836 | 2026-04-30 |
| Pacer Advisors, Inc. | 0.02% | 482 153 | 2026-06-30 |
| Partners Capital Investm… | 0% | 24 335 | 2026-06-30 |
| Paradigm Asset Managemen… | 0% | 21 514 | 2026-06-30 |
| Generali Investments Cee… | 0% | 15 729 | 2026-06-30 |
